Melphalan Zentiva

Melphalan Hydrochloride, the active ingredient in Melphalan Zentiva, is an alkylating agent (nitrogen mustard) presented as an intravenous solution for injection use. It treats multiple myeloma, ovarian cancer, malignant melanoma, and neuroblastoma in adult patients.

GNH USA supplies Melphalan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Melphalan Zentiva is an alkylating chemotherapy used for several solid‑tumour and haematologic malignancies.

- Multiple myeloma: provides cytoreductive activity to reduce malignant plasma cells. - Ovarian cancer: used in combination regimens to achieve tumour shrinkage. - Malignant melanoma: employed in advanced disease to induce tumour cell death. - Neuroblastoma: administered in high‑risk cases to improve remission rates.

Melphalan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during treatment. - Alopecia: reversible hair loss affecting scalp and body hair. - Myelosuppression: reduced white blood cells, red cells, and platelets. - Fatigue: generalized tiredness often reported. - Mucositis: inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects: - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Thrombocytopenia: low platelet count leading to bleeding complications. - Secondary malignancies: rare development of new cancers after therapy. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal toxicity: impaired kidney function in susceptible patients.

Careful monitoring and patient assessment are essential when using Melphalan Zentiva.

- Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess renal function: check serum creatinine and adjust dosing if needed. - Evaluate hepatic function: liver impairment may affect drug clearance. - Avoid in hypersensitivity: discontinue if allergic reactions occur. - Use contraception: advise both male and female patients to use effective birth control during treatment and for a defined period after. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Melphalan can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent myelosuppressive agents: increase risk of severe bone‑marrow suppression. - High‑dose radiation therapy: synergistic toxicity to normal tissues. - Live attenuated vaccines: may cause uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate gastrointestinal irritation. - ACE inhibitors or ARBs: potential additive renal toxicity. - Antacids: could affect the stability of the intravenous solution if mixed improperly.